{"id":5187,"date":"2026-02-06T22:32:35","date_gmt":"2026-02-07T04:32:35","guid":{"rendered":"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/?p=5187"},"modified":"2026-02-07T03:27:32","modified_gmt":"2026-02-07T09:27:32","slug":"zepbound-vs-wegovy","status":"publish","type":"post","link":"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/zepbound-vs-wegovy\/","title":{"rendered":"Zepbound vs Wegovy: 20% vs 14% Weight Loss &#8211; Head-to-Head Trial"},"content":{"rendered":"<p><span style=\"font-weight: 400;\">Zepbound beats Wegovy with 20.2% vs 13.7% body weight loss in the first-ever head-to-head trial (SURMOUNT-5), published in the New England Journal of Medicine. The key difference: Zepbound is a dual GLP-1 and GIP receptor agonist, while Wegovy targets only GLP-1. Both are FDA-approved injectable weight loss medications that require weekly injections alongside healthy eating and increased physical activity.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">On average, participants on Zepbound lost 50.3 pounds compared to 33.1 pounds for those on Wegovy over 72 weeks. Approximately 32% of adults with obesity on Zepbound achieved at least 25% body weight reduction, double the 16% rate seen with Wegovy. However, Wegovy has unique FDA approval to reduce cardiovascular disease risk, while Zepbound is approved for treating moderate-to-severe obstructive sleep apnea.<\/span><\/p>\n<h2><b>TL;DR: Quick Summary<\/b><\/h2>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Zepbound (tirzepatide) outperforms Wegovy (semaglutide) in the <\/span><b>SURMOUNT-5 head-to-head clinical trial<\/b><span style=\"font-weight: 400;\"> with 20.2% average body weight loss vs. 13.7% for Wegovy at 72 weeks.\u00a0<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Zepbound&#8217;s dual GLP-1\/GIP mechanism<\/b><span style=\"font-weight: 400;\"> delivers 47% greater relative weight loss. Both FDA-approved for long-term weight management.\u00a0<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Wegovy has cardiovascular protection approval; Zepbound has obstructive sleep apnea approval.\u00a0<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Cost: ~$1,086\/month (Zepbound) vs. ~$1,349\/month (Wegovy) list price, but most pay $25-50 with insurance and savings programs.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/product\/zepbound\/\"><span style=\"font-weight: 400;\">Zepbound<\/span><\/a><span style=\"font-weight: 400;\"> is available at Pandameds.com for only $559.99, while <\/span><a href=\"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/product\/wegovy\/\"><span style=\"font-weight: 400;\">Wegovy<\/span><\/a><span style=\"font-weight: 400;\"> is available at $599.95.<\/span><\/li>\n<\/ul>\n<h2><b>Zepbound vs Wegovy Mechanism Differences<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">The fundamental difference between Zepbound and Wegovy lies in how they work at the receptor level. Zepbound (tirzepatide<a href=\"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/product\/zepbound\/\">)<\/a> is a <\/span><b>dual agonist<\/b><span style=\"font-weight: 400;\"> that mimics two hormones: glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Wegovy (semaglutide) is a <\/span><b>single agonist<\/b><span style=\"font-weight: 400;\"> targeting only GLP-1.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Both GLP-1 and GIP receptors are found in brain areas important for appetite regulation. According to research from<\/span><a href=\"https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lillys-zepboundr-tirzepatide-superior-wegovyr-semaglutide-head\"> <span style=\"font-weight: 400;\">Eli Lilly<\/span><\/a><span style=\"font-weight: 400;\">, this dual-action approach helps decrease calorie intake more effectively by affecting appetite through two pathways. Both medications slow digestion and help regulate blood sugar levels, leading to decreased appetite and reduced food consumption.<\/span><\/p>\n<p><b>Mechanism Comparison<\/b><\/p>\n<table>\n<tbody>\n<tr>\n<td><b>Feature<\/b><\/td>\n<td><b>Zepbound (Tirzepatide)<\/b><\/td>\n<td><b>Wegovy (Semaglutide)<\/b><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Mechanism<\/span><\/td>\n<td><span style=\"font-weight: 400;\">GLP-1 + GIP dual agonist<\/span><\/td>\n<td><span style=\"font-weight: 400;\">GLP-1 only<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Weight Loss (72 wks)<\/span><\/td>\n<td><span style=\"font-weight: 400;\">20.2%<\/span><\/td>\n<td><span style=\"font-weight: 400;\">13.7%<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Maximum Dose<\/span><\/td>\n<td><span style=\"font-weight: 400;\">15 mg weekly<\/span><\/td>\n<td><span style=\"font-weight: 400;\">2.4 mg weekly<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">FDA Approvals<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Weight loss + Sleep Apnea<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Weight loss + Cardiovascular<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Manufacturer<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Eli Lilly<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Novo Nordisk<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><span style=\"font-weight: 400;\">Source:<\/span><a href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/217806s003lbl.pdf\"> <span style=\"font-weight: 400;\">FDA Prescribing Information<\/span><\/a><\/p>\n<h2><b>Weight Loss Results &#8211; Head-to-Head Trial<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">The<\/span><a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2502530\"> <span style=\"font-weight: 400;\">SURMOUNT-5 trial<\/span><\/a><span style=\"font-weight: 400;\"> published in the New England Journal of Medicine represents the first direct comparison between these new weight loss drugs. Led by Dr. Louis Aronne, director of the Comprehensive Weight Control Center at Weill Cornell Medicine, the 72-week study enrolled 751 adults with obesity or overweight with at least one weight-related health condition.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Results confirmed Zepbound&#8217;s superior efficacy. Participants treated with Zepbound lost an average of 50.3 pounds (22.8 kg), while those on Wegovy lost 33.1 pounds (15 kg). The trial demonstrated how much weight can be lost with each medication, with Zepbound helping people lose approximately 6.5% more body weight than Wegovy.<\/span><\/p>\n<p><b>SURMOUNT-5 Clinical Results<\/b><\/p>\n<table>\n<tbody>\n<tr>\n<td><b>Metric<\/b><\/td>\n<td><b>Zepbound<\/b><\/td>\n<td><b>Wegovy<\/b><\/td>\n<td><b>Significance<\/b><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">72-Week Weight Loss<\/span><\/td>\n<td><span style=\"font-weight: 400;\">20.2%<\/span><\/td>\n<td><span style=\"font-weight: 400;\">13.7%<\/span><\/td>\n<td><span style=\"font-weight: 400;\">P&lt;0.001<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Average Pounds Lost<\/span><\/td>\n<td><span style=\"font-weight: 400;\">50.3 lbs<\/span><\/td>\n<td><span style=\"font-weight: 400;\">33.1 lbs<\/span><\/td>\n<td><span style=\"font-weight: 400;\">47% more<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">\u226525% Weight Loss<\/span><\/td>\n<td><span style=\"font-weight: 400;\">32%<\/span><\/td>\n<td><span style=\"font-weight: 400;\">16%<\/span><\/td>\n<td><span style=\"font-weight: 400;\">2x superior<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Waist Reduction<\/span><\/td>\n<td><span style=\"font-weight: 400;\">18.4 cm<\/span><\/td>\n<td><span style=\"font-weight: 400;\">13.0 cm<\/span><\/td>\n<td><span style=\"font-weight: 400;\">42% more<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><span style=\"font-weight: 400;\">Source:<\/span><a href=\"https:\/\/news.weill.cornell.edu\/news\/2025\/05\/head-to-head-trial-compares-weight-loss-drugs\"> <span style=\"font-weight: 400;\">Weill Cornell Medicine \/ NEJM May 2025<\/span><\/a><\/p>\n<h2><span style=\"font-weight: 400;\">Side Effects Comparison &#8211; Identical GI Profile<\/span><\/h2>\n<p><span style=\"font-weight: 400;\">The most common side effects of Zepbound and Wegovy are virtually identical, primarily gastrointestinal in nature. Both medications cause nausea, vomiting, diarrhea, constipation, and abdominal pain as the body adjusts to the medication. These side effects are generally mild to moderate and tend to resolve by week 12 as the dose is gradually increased.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Serious side effects may include pancreatitis, gallbladder problems, kidney problems, and severe allergic reactions. Both medications carry an FDA warning about a possible link to thyroid C-cell tumors, including medullary thyroid carcinoma. Patients with a family history of these conditions or multiple endocrine neoplasia syndrome type 2 should not use these medications.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Importantly, fewer patients on Zepbound discontinued treatment due to adverse events compared to Wegovy. Both may cause mood changes or suicidal ideation in rare cases. Zepbound may increase the risk of low blood sugar when taken with insulin or sulfonylureas and may reduce the effectiveness of oral contraceptives.<\/span><\/p>\n<p><b>Safety Profile Comparison<\/b><\/p>\n<table>\n<tbody>\n<tr>\n<td><b>Side Effect<\/b><\/td>\n<td><b>Zepbound<\/b><\/td>\n<td><b>Wegovy<\/b><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Nausea<\/span><\/td>\n<td><span style=\"font-weight: 400;\">45%<\/span><\/td>\n<td><span style=\"font-weight: 400;\">44%<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Diarrhea<\/span><\/td>\n<td><span style=\"font-weight: 400;\">23%<\/span><\/td>\n<td><span style=\"font-weight: 400;\">20%<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Constipation<\/span><\/td>\n<td><span style=\"font-weight: 400;\">17%<\/span><\/td>\n<td><span style=\"font-weight: 400;\">16%<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Discontinuation Rate<\/span><\/td>\n<td><span style=\"font-weight: 400;\">~7%<\/span><\/td>\n<td><span style=\"font-weight: 400;\">~7%<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><span style=\"font-weight: 400;\">Note: Side effects are generally mild-moderate and resolve as dosage stabilizes. Source:<\/span><a href=\"https:\/\/investor.lilly.com\/news-releases\/news-release-details\/zepbound-tirzepatide-showed-superior-weight-loss-over-wegovy\"> <span style=\"font-weight: 400;\">SURMOUNT-5 Trial Data<\/span><\/a><\/p>\n<h2><span style=\"font-weight: 400;\">Zepbound vs Wegovy Insurance Coverage 2026<\/span><\/h2>\n<p><span style=\"font-weight: 400;\">Insurance coverage for GLP-1 weight loss medications varies widely. Wegovy generally has better commercial insurance acceptance due to its longer track record, though Zepbound is rapidly gaining ground. Major developments in late 2025 significantly changed the coverage landscape.<\/span><\/p>\n<p><b>Key Coverage Update (November 2025): <\/b><span style=\"font-weight: 400;\">The federal government announced that Medicare will now cover Wegovy and Zepbound for beneficiaries with obesity and at least one weight-related comorbidity. Medicare beneficiaries pay approximately $50\/month under the new program. Previously, Medicare did not cover weight-loss medications at all.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Medicaid coverage depends on your state. Some states, like California (Medi-Cal), cover Zepbound for weight management with no prior approval. Other states may only cover these medications for the obstructive sleep apnea indication or require step therapy.<\/span><\/p>\n<p><b>Insurance Coverage Comparison<\/b><\/p>\n<table>\n<tbody>\n<tr>\n<td><b>Insurance Type<\/b><\/td>\n<td><b>Zepbound Coverage<\/b><\/td>\n<td><b>Wegovy Coverage<\/b><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Commercial Plans<\/span><\/td>\n<td><span style=\"font-weight: 400;\">~45%<\/span><\/td>\n<td><span style=\"font-weight: 400;\">~55%<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Medicare (2026)<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Yes (with comorbidity)<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Yes (with comorbidity)<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Employer Plans<\/span><\/td>\n<td><span style=\"font-weight: 400;\">~50%<\/span><\/td>\n<td><span style=\"font-weight: 400;\">~65%<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><span style=\"font-weight: 400;\">Source:<\/span><a href=\"https:\/\/zepbound.lilly.com\/access-coverage\"> <span style=\"font-weight: 400;\">Lilly Coverage Information<\/span><\/a><span style=\"font-weight: 400;\"> and<\/span><a href=\"https:\/\/www.whitehouse.gov\/fact-sheets\/2025\/11\/fact-sheet-president-donald-j-trump-announces-major-developments-in-bringing-most-favored-nation-pricing-to-american-patients\/\"> <span style=\"font-weight: 400;\">White House GLP-1 Announcement<\/span><\/a><\/p>\n<h2><span style=\"font-weight: 400;\">Cost Comparison &#8211; Near Identical List Prices<\/span><\/h2>\n<p><span style=\"font-weight: 400;\">The list price of Zepbound is approximately $1,086 per month, while Wegovy costs around $1,349 per month. However, most patients won&#8217;t pay these full amounts thanks to insurance coverage and manufacturer savings programs.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">With commercial insurance coverage, patients can pay as little as $25\/month for Zepbound or $0 for Wegovy using manufacturer savings cards. Without insurance,<\/span><a href=\"https:\/\/zepbound.lilly.com\/savings\"> <span style=\"font-weight: 400;\">LillyDirect<\/span><\/a><span style=\"font-weight: 400;\"> offers Zepbound vials starting at $349\/month (for 2.5mg) to $449\/month (for higher doses). Novo Nordisk recently reduced cash prices for Wegovy to $349\/month for existing patients.<\/span><\/p>\n<p><b>Cost Comparison<\/b><\/p>\n<table>\n<tbody>\n<tr>\n<td><b>Pricing Scenario<\/b><\/td>\n<td><b>Zepbound<\/b><\/td>\n<td><b>Wegovy<\/b><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">List Price<\/span><\/td>\n<td><span style=\"font-weight: 400;\">$1,086\/month<\/span><\/td>\n<td><span style=\"font-weight: 400;\">$1,349\/month<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Pandameds.com<\/span><\/td>\n<td><span style=\"font-weight: 400;\">$559.99<\/span><\/td>\n<td><span style=\"font-weight: 400;\">$599.95<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">With Savings Card<\/span><\/td>\n<td><span style=\"font-weight: 400;\">As low as $25<\/span><\/td>\n<td><span style=\"font-weight: 400;\">As low as $0<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Cash (Direct)<\/span><\/td>\n<td><span style=\"font-weight: 400;\">$349-$449 (vials)<\/span><\/td>\n<td><span style=\"font-weight: 400;\">$349-$499<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Medicare (2026)<\/span><\/td>\n<td><span style=\"font-weight: 400;\">~$50 copay<\/span><\/td>\n<td><span style=\"font-weight: 400;\">~$50 copay<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><b>Switching Between Zepbound \u2194 Wegovy<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">Patients may need to switch between Zepbound and Wegovy for various reasons, including insurance changes, side effect management, or seeking better results. The good news: no washout period is required when switching between these medications.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">When switching from <a href=\"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/product\/wegovy\/\">Wegovy 2.4mg<\/a> to Zepbound, healthcare providers typically start at 5mg. When switching from Zepbound to Wegovy, the usual starting dose is 1.0mg. Patients should expect 2-3 weeks of GI symptoms overlap as the body adjusts to the new medication. Blood sugar should be monitored closely during the first month, especially in patients who treat diabetes.<\/span><\/p>\n<p><b>Switching Protocol<\/b><\/p>\n<table>\n<tbody>\n<tr>\n<td><b>Switch Direction<\/b><\/td>\n<td><b>Starting Dose<\/b><\/td>\n<td><b>Timing<\/b><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Wegovy \u2192 Zepbound<\/span><\/td>\n<td><span style=\"font-weight: 400;\">5 mg<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Day 1 (no washout)<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Zepbound \u2192 Wegovy<\/span><\/td>\n<td><span style=\"font-weight: 400;\">1.0 mg<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Day 1 (no washout)<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><span style=\"font-weight: 400;\">Note: Consult your healthcare provider before switching. Dose adjustments should be individualized.<\/span><\/p>\n<h2><b>FDA Approvals: Key Differences<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">Both Zepbound and Wegovy gained FDA approval for long-term weight management in adults with obesity (BMI \u226530) or overweight (BMI \u226527) with at least one weight-related comorbid condition. However, each has unique additional approvals:<\/span><\/p>\n<p><a href=\"https:\/\/investor.lilly.com\/news-releases\/news-release-details\/fda-approves-zepboundr-tirzepatide-first-and-only-prescription\"><b>Zepbound (December 2024)<\/b><\/a><b>: <\/b><span style=\"font-weight: 400;\">FDA approved as the first and only prescription medicine for treating moderate-to-severe obstructive sleep apnea in adults with obesity. This makes Zepbound a better option for individuals with sleep apnea.<\/span><\/p>\n<p><a href=\"https:\/\/www.novonordisk.com\/news-and-media\/news-and-ir-materials\/news-details.html?id=167030\"><b>Wegovy (March 2024)<\/b><\/a><b>: <\/b><span style=\"font-weight: 400;\">FDA approved to reduce the risk of major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in adults with established cardiovascular disease and either obesity or overweight. This makes Wegovy more suitable for those with heart disease or high cardiovascular risk.<\/span><\/p>\n<h2><span style=\"font-weight: 400;\">Which Is Right for You? Decision Framework<\/span><\/h2>\n<h3><span style=\"font-weight: 400;\">Zepbound may be better if you:\u00a0<\/span><\/h3>\n<p><span style=\"font-weight: 400;\">want maximum weight loss results, have obstructive sleep apnea, prefer a dual-hormone approach, or have tried GLP-1-only medications without sufficient results.<\/span><\/p>\n<h3><span style=\"font-weight: 400;\">Wegovy may be better if you:\u00a0<\/span><\/h3>\n<p><span style=\"font-weight: 400;\">have cardiovascular disease or high heart risk, need better insurance coverage, prefer a medication with longer market history, or are focused on reducing risk of heart attack and stroke.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Both medications require healthy lifestyle changes including a reduced-calorie diet and regular physical activity for long-term weight management success. Neither is a standalone solution-stress management, healthy eating, and exercise remain essential components of treating obesity.<\/span><\/p>\n<h2>References &amp; Sources<\/h2>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.nejm.org\/\"><span style=\"font-weight: 400;\">SURMOUNT-5 Trial Results (2025). New England Journal of Medicine<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lillys-zepboundr-tirzepatide-superior-wegovyr-semaglutide-head\"><span style=\"font-weight: 400;\">Eli Lilly Press Release (Dec 2024). SURMOUNT-5 Topline Results.<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/217806s003lbl.pdf\"><span style=\"font-weight: 400;\">FDA. Zepbound Prescribing Information (2024). accessdata.fda.gov.<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/215256s011lbl.pdf\"><span style=\"font-weight: 400;\">FDA. Wegovy Prescribing Information (2024). accessdata.fda.gov.<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.novonordisk.com\/news-and-media\/news-and-ir-materials\/news-details.html?id=167030\"><span style=\"font-weight: 400;\">Novo Nordisk (Mar 2024). Wegovy Cardiovascular Approval.<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/news.weill.cornell.edu\/news\/2025\/05\/head-to-head-trial-compares-weight-loss-drugs\"><span style=\"font-weight: 400;\">Weill Cornell Medicine (May 2025). Head-to-Head Trial Results.<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/zepbound.lilly.com\/savings\"><span style=\"font-weight: 400;\">Eli Lilly. Zepbound Savings Programs.<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.whitehouse.gov\/fact-sheets\/2025\/11\/fact-sheet-president-donald-j-trump-announces-major-developments-in-bringing-most-favored-nation-pricing-to-american-patients\/\"><span style=\"font-weight: 400;\">White House (Nov 2025). GLP-1 Medicare Coverage Announcement.<\/span><\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Zepbound beats Wegovy with 20.2% vs 13.7% body weight loss [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":5406,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12,26,34,35],"tags":[],"class_list":["post-5187","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog","category-wegovy","category-zepbound","category-zepbound-blog"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Zepbound vs Wegovy: Zepbound 20% vs Wegovy 14% Weight Loss Trial<\/title>\n<meta name=\"description\" content=\"Zepbound vs Wegovy: Zepbound wins with 20% weight loss vs Wegovy&#039;s 14% in head-to-head trials. Compare side effects, cost, dosage, results &amp; which is best for you.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/zepbound-vs-wegovy\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Zepbound vs Wegovy: Zepbound 20% vs Wegovy 14% Weight Loss Trial\" \/>\n<meta property=\"og:description\" content=\"Zepbound vs Wegovy: Zepbound wins with 20% weight loss vs Wegovy&#039;s 14% in head-to-head trials. Compare side effects, cost, dosage, results &amp; which is best for you.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/zepbound-vs-wegovy\/\" \/>\n<meta property=\"og:site_name\" content=\"Pandameds.com\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/Pandameds99\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-07T04:32:35+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-07T09:27:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/wp-content\/uploads\/2026\/02\/Zepbound-vs-Wegovy.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1048\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Dr. Kristianne Hannemann, PharmD\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@Pandameds99\" \/>\n<meta name=\"twitter:site\" content=\"@Pandameds99\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Dr. Kristianne Hannemann, PharmD\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/zepbound-vs-wegovy\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/zepbound-vs-wegovy\/\"},\"author\":{\"name\":\"Dr. Kristianne Hannemann, PharmD\",\"@id\":\"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/#\/schema\/person\/595d02444f7800cd1596caa88e2eec8a\"},\"headline\":\"Zepbound vs Wegovy: 20% vs 14% Weight Loss &#8211; Head-to-Head Trial\",\"datePublished\":\"2026-02-07T04:32:35+00:00\",\"dateModified\":\"2026-02-07T09:27:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/zepbound-vs-wegovy\/\"},\"wordCount\":1343,\"publisher\":{\"@id\":\"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/#organization\"},\"image\":{\"@id\":\"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/zepbound-vs-wegovy\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/wp-content\/uploads\/2026\/02\/Zepbound-vs-Wegovy.webp\",\"articleSection\":[\"Blog\",\"Wegovy\",\"Zepbound\",\"Zepbound\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/zepbound-vs-wegovy\/\",\"url\":\"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/zepbound-vs-wegovy\/\",\"name\":\"Zepbound vs Wegovy: Zepbound 20% vs Wegovy 14% Weight Loss Trial\",\"isPartOf\":{\"@id\":\"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/zepbound-vs-wegovy\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/zepbound-vs-wegovy\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/wp-content\/uploads\/2026\/02\/Zepbound-vs-Wegovy.webp\",\"datePublished\":\"2026-02-07T04:32:35+00:00\",\"dateModified\":\"2026-02-07T09:27:32+00:00\",\"description\":\"Zepbound vs Wegovy: Zepbound wins with 20% weight loss vs Wegovy's 14% in head-to-head trials. Compare side effects, cost, dosage, results & which is best for you.\",\"breadcrumb\":{\"@id\":\"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/zepbound-vs-wegovy\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/zepbound-vs-wegovy\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/zepbound-vs-wegovy\/#primaryimage\",\"url\":\"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/wp-content\/uploads\/2026\/02\/Zepbound-vs-Wegovy.webp\",\"contentUrl\":\"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/wp-content\/uploads\/2026\/02\/Zepbound-vs-Wegovy.webp\",\"width\":1920,\"height\":1048,\"caption\":\"Zepbound vs Wegovy\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/zepbound-vs-wegovy\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Zepbound vs Wegovy: 20% vs 14% Weight Loss &#8211; Head-to-Head Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/#website\",\"url\":\"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/\",\"name\":\"Pandameds.com\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/#organization\"},\"alternateName\":\"Pandameds\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/#organization\",\"name\":\"Pandameds.com\",\"alternateName\":\"PandaMeds\",\"url\":\"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/wp-content\/uploads\/2024\/06\/logo.png\",\"contentUrl\":\"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/wp-content\/uploads\/2024\/06\/logo.png\",\"width\":182,\"height\":30,\"caption\":\"Pandameds.com\"},\"image\":{\"@id\":\"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/Pandameds99\/\",\"https:\/\/x.com\/Pandameds99\",\"https:\/\/www.instagram.com\/_pandameds\/\",\"https:\/\/www.trustpilot.com\/review\/pandameds.com\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/#\/schema\/person\/595d02444f7800cd1596caa88e2eec8a\",\"name\":\"Dr. Kristianne Hannemann, PharmD\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/44fad3a014590315d539c61523c0d78633fc5a6a9b9f58f18f6b92deac1c21e7?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/44fad3a014590315d539c61523c0d78633fc5a6a9b9f58f18f6b92deac1c21e7?s=96&d=mm&r=g\",\"caption\":\"Dr. Kristianne Hannemann, PharmD\"},\"description\":\"Dr. Kristianne Hannemann is a licensed pharmacist with over seven years of experience in community pharmacy and patient education. She specializes in medical writing and drug information. Dr. Hannemann is passionate about delivering current, evidence-based medication information in a clear, accessible format, empowering patients to confidently navigate their health journey.\",\"sameAs\":[\"https:\/\/www.linkedin.com\/in\/kristianne-hannemann\/\"],\"url\":\"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/kristianne-hannemann\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Zepbound vs Wegovy: Zepbound 20% vs Wegovy 14% Weight Loss Trial","description":"Zepbound vs Wegovy: Zepbound wins with 20% weight loss vs Wegovy's 14% in head-to-head trials. Compare side effects, cost, dosage, results & which is best for you.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/zepbound-vs-wegovy\/","og_locale":"en_US","og_type":"article","og_title":"Zepbound vs Wegovy: Zepbound 20% vs Wegovy 14% Weight Loss Trial","og_description":"Zepbound vs Wegovy: Zepbound wins with 20% weight loss vs Wegovy's 14% in head-to-head trials. Compare side effects, cost, dosage, results & which is best for you.","og_url":"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/zepbound-vs-wegovy\/","og_site_name":"Pandameds.com","article_publisher":"https:\/\/www.facebook.com\/Pandameds99\/","article_published_time":"2026-02-07T04:32:35+00:00","article_modified_time":"2026-02-07T09:27:32+00:00","og_image":[{"width":1920,"height":1048,"url":"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/wp-content\/uploads\/2026\/02\/Zepbound-vs-Wegovy.webp","type":"image\/webp"}],"author":"Dr. Kristianne Hannemann, PharmD","twitter_card":"summary_large_image","twitter_creator":"@Pandameds99","twitter_site":"@Pandameds99","twitter_misc":{"Written by":"Dr. Kristianne Hannemann, PharmD","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/zepbound-vs-wegovy\/#article","isPartOf":{"@id":"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/zepbound-vs-wegovy\/"},"author":{"name":"Dr. Kristianne Hannemann, PharmD","@id":"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/#\/schema\/person\/595d02444f7800cd1596caa88e2eec8a"},"headline":"Zepbound vs Wegovy: 20% vs 14% Weight Loss &#8211; Head-to-Head Trial","datePublished":"2026-02-07T04:32:35+00:00","dateModified":"2026-02-07T09:27:32+00:00","mainEntityOfPage":{"@id":"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/zepbound-vs-wegovy\/"},"wordCount":1343,"publisher":{"@id":"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/#organization"},"image":{"@id":"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/zepbound-vs-wegovy\/#primaryimage"},"thumbnailUrl":"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/wp-content\/uploads\/2026\/02\/Zepbound-vs-Wegovy.webp","articleSection":["Blog","Wegovy","Zepbound","Zepbound"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/zepbound-vs-wegovy\/","url":"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/zepbound-vs-wegovy\/","name":"Zepbound vs Wegovy: Zepbound 20% vs Wegovy 14% Weight Loss Trial","isPartOf":{"@id":"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/#website"},"primaryImageOfPage":{"@id":"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/zepbound-vs-wegovy\/#primaryimage"},"image":{"@id":"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/zepbound-vs-wegovy\/#primaryimage"},"thumbnailUrl":"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/wp-content\/uploads\/2026\/02\/Zepbound-vs-Wegovy.webp","datePublished":"2026-02-07T04:32:35+00:00","dateModified":"2026-02-07T09:27:32+00:00","description":"Zepbound vs Wegovy: Zepbound wins with 20% weight loss vs Wegovy's 14% in head-to-head trials. Compare side effects, cost, dosage, results & which is best for you.","breadcrumb":{"@id":"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/zepbound-vs-wegovy\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/demo5.newmediaguru.co\/pandameds-wp\/zepbound-vs-wegovy\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/zepbound-vs-wegovy\/#primaryimage","url":"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/wp-content\/uploads\/2026\/02\/Zepbound-vs-Wegovy.webp","contentUrl":"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/wp-content\/uploads\/2026\/02\/Zepbound-vs-Wegovy.webp","width":1920,"height":1048,"caption":"Zepbound vs Wegovy"},{"@type":"BreadcrumbList","@id":"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/zepbound-vs-wegovy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/"},{"@type":"ListItem","position":2,"name":"Zepbound vs Wegovy: 20% vs 14% Weight Loss &#8211; Head-to-Head Trial"}]},{"@type":"WebSite","@id":"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/#website","url":"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/","name":"Pandameds.com","description":"","publisher":{"@id":"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/#organization"},"alternateName":"Pandameds","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/#organization","name":"Pandameds.com","alternateName":"PandaMeds","url":"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/#\/schema\/logo\/image\/","url":"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/wp-content\/uploads\/2024\/06\/logo.png","contentUrl":"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/wp-content\/uploads\/2024\/06\/logo.png","width":182,"height":30,"caption":"Pandameds.com"},"image":{"@id":"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/Pandameds99\/","https:\/\/x.com\/Pandameds99","https:\/\/www.instagram.com\/_pandameds\/","https:\/\/www.trustpilot.com\/review\/pandameds.com"]},{"@type":"Person","@id":"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/#\/schema\/person\/595d02444f7800cd1596caa88e2eec8a","name":"Dr. Kristianne Hannemann, PharmD","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/44fad3a014590315d539c61523c0d78633fc5a6a9b9f58f18f6b92deac1c21e7?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/44fad3a014590315d539c61523c0d78633fc5a6a9b9f58f18f6b92deac1c21e7?s=96&d=mm&r=g","caption":"Dr. Kristianne Hannemann, PharmD"},"description":"Dr. Kristianne Hannemann is a licensed pharmacist with over seven years of experience in community pharmacy and patient education. She specializes in medical writing and drug information. Dr. Hannemann is passionate about delivering current, evidence-based medication information in a clear, accessible format, empowering patients to confidently navigate their health journey.","sameAs":["https:\/\/www.linkedin.com\/in\/kristianne-hannemann\/"],"url":"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/kristianne-hannemann\/"}]}},"_links":{"self":[{"href":"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/wp-json\/wp\/v2\/posts\/5187","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/wp-json\/wp\/v2\/comments?post=5187"}],"version-history":[{"count":4,"href":"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/wp-json\/wp\/v2\/posts\/5187\/revisions"}],"predecessor-version":[{"id":5227,"href":"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/wp-json\/wp\/v2\/posts\/5187\/revisions\/5227"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/wp-json\/wp\/v2\/media\/5406"}],"wp:attachment":[{"href":"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/wp-json\/wp\/v2\/media?parent=5187"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/wp-json\/wp\/v2\/categories?post=5187"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/demo5.newmediaguru.co\/pandameds-wp\/wp-json\/wp\/v2\/tags?post=5187"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}